| Name | Title | Contact Details |
|---|
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
BioWa is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ikaria is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
TLC Biopharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biotie Therapies is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.